bearish
SanBio (4592 JP): Remains Unlucky for Second-Time; Delay in First Product Approval Weighs Heavily
218 Views02 Nov 2022 09:46
SUMMARY
- In March, SanBio Co Ltd (4592 JP) completed the application filing for approval for its investigational product SB623, as a treatment for chronic motor deficit from traumatic brain injury.
- With a priority review designation, SB623 approval was expected in September. SanBio is expecting a delay in the approval. SB623 is now expected to be approved next year.
- For FY23, the company is now expecting operating expenses of ¥8.1 billion, which exceeds the earlier expectations by ¥2.2 billion due to an anticipated increase in manufacturing-related expenses.
Related Insights
More »Loading
Trending Collections
More »Loading
Trending Insights
More »Loading
Top Unpaywalled Insights
More »Loading
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- SanBio Co Ltd (4592 JP): Losses Narrow; AKUUGO Upbeat on Successful Commercial Runs; FY26 Key19 Mar 2025
- SanBio Co Ltd (4592 JP): Conditional Approval for First Drug; Still a Long Way to Go20 Sep 2024
- SanBio (4592 JP): Better-Than-Expected Operating Loss in FY23; Product Approval Expected in FY2417 Mar 2023
- SanBio (4592 JP): Remains Unlucky for Second-Time; Delay in First Product Approval Weighs Heavily02 Nov 2022
- SanBio (4592 JP): Marketing Approval of First Product Expected This Year in Japan15 Apr 2022
x